This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

514G3

XBiotech, Inc.

Drug Names(s): MRSA Antibody

Description: The MRSA (methicillin resistant staphylococcus aureus) antibody is designed to neutralize the drug resistant staphylococcus allowing for natural clearance of the bacteria by the immune system.

The antibody is based on XBiotech's proprietary discovery platform for True Human antibodies.

Deal Structure: XBiotech and Strox
In April 2014, XBiotech announced that it has acquired the patent estate of Strox Biopharmaceuticals relating to antibody therapies for methicillin resistant staphylococcus aureus (MRSA). Included in the deal are both issued and pending patents for antibody technologies useful for either prophylaxis or therapeutic intervention for resistant and potentially life threatening infections. Terms of the in-licensing agreement are reported to include an upfront cash payment, royalty on sales and XBiotech will assume costs and responsibilities for all patent prosecution and maintenance.

Partners: Strox Pharmaceuticals, LLC


514G3 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug